Roche's Vabysmo, Susvimo helps maintain vision with fewer treatments in phase 3 studies ...

Retrieved on: 2022-02-11 11:51:45

Tags for this article:

Click the tags to see associated articles and topics

Roche's Vabysmo, Susvimo helps maintain vision with fewer treatments in phase 3 studies .... View article details on hiswai:

Excerpt

Roche's (RHHBY) (RHHBF) unit Genentech reported positive two-year data from its phase 3 studies of Vabysmo (faricimab-svoa) and Susvimo ...

Article found on: seekingalpha.com